

Human Anti-Vedolizumab monoclonal antibody, clone AbD30136 (CABT-ZB1177)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	Vedolizumab
Target	Vedolizumab
Immunogen	Vedolizumab
Isotype	Fab
Source/Host	Human
Species Reactivity	N/A
Clone	AbD30136
Affinity Constant	The monovalent intrinsic affinity of AbD30136 was measured as KD=0.1 nM by real time, label-free molecular interaction analysis on immobilized vedolizumab.
Purification	Metal chelate affinity chromatography
Conjugate	Unconjugated
Applications	Suitable for PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB1177 - CABT-ZB1179 / CABT-ZB1180 / CABT-ZB1181 / CABT-ZB1178 Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Format	Liquid
Concentration	Lot specific

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221

Size	100 µg
Buffer	PBS
Preservative	0.01% Thiomersal
Storage	Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -21°C.
Ship	Wet ice

BACKGROUND

Introduction	Vedolizumab (Entyvio) is a humanized antibody (IgG1/kappa), derived from a murine antibody. It is used for the treatment of both moderate to severe ulcerative colitis and moderate to severe Crohn's disease, primarily in patients who have lost response to, or are intolerant to inhibitors of tumor necrosis factor alpha (TNFα), such as infliximab. The drug binds specifically to human α4β7 integrin, a key mediator of gastrointestinal inflammation expressed on the surfaces of T and B lymphocytes. By selectively inhibiting the binding of α4β7 integrin to the mucosal addressin cell adhesion molecule-1 (MAdCAM-1), vedolizumab prevents leukocyte binding to the endothelial surface and extravasation into affected tissue. Specifically inhibiting this pathway alleviates gastrointestinal inflammation without impairing systemic immune responses.
Keywords	Vedolizumab; Entyvio

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221